New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Two preventive tools — a maternal vaccine and a monoclonal antibody — were tied to a recent drop in RSV hospitalization rates for U.S. babies.

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

Babies treated with nirsevimab had an 83% reduced risk of hospitalization due to RSV infection, researchers reported May 1 in The Lancet Child & Adolescent Health. The antibody treatment also ...

Toddlers with chronic conditions are hospitalized for RSV at twice the rate as healthy toddlers over their first two seasons. The risk was highest for children born very prematurely under 28 weeks ...

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Young children with chronic conditions are more likely to be hospitalized for respiratory syncytial virus (RSV) than healthy children, according to a new study. The research will be presented at ...

New Delhi, April 25 : Young children with chronic conditions are more likely to be hospitalised for respiratory syncytial virus (RSV) than healthy children, according to a new study on Friday. The ...